Texts and brain zaps: new combo for tough depression?

NCT ID NCT05570344

Recruiting now Symptom relief Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a supportive text-messaging program (Text4Support) to repetitive transcranial magnetic stimulation (rTMS) improves depression symptoms more than rTMS alone. About 200 adults with treatment-resistant depression will be randomly assigned to one of two groups. The trial lasts 6 weeks of active treatment, with follow-ups at 1, 3, and 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Repetitive transcranial magnetic stimulation (rTMS) and Text4Support (supportive text messages)
What this could lead to: If it works, this could point toward a more effective, low-cost way to ease depression symptoms in people who haven't responded to standard treatments.
What could go wrong: This is a small, early pilot trial, so results may not apply widely. Adding text messages may not provide extra benefit over rTMS alone, and the study is not designed to prove long-term effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, TREATMENT-RESISTANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

depressive disorder Depressive Disorder, Treatment-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSIVE DISORDER, TREATMENT-RESISTANT

Contacts and locations

Locations

Edmonton Mental Health Clinic
RECRUITING

Edmonton, Alberta, T6R 3P5, Canada
Nova Scotia Health - Abbie J. Lane Memorial Building QEII Health Sciences Centre
RECRUITING

Halifax, Nova Scotia, B3H 2E2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.